RecruitingEarly Phase 1NCT07274813

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX37 (Recombinant Human Bispecific Antibodies Against PD-L1 and VEGF) in Patients With Advanced/Metastatic Solid Tumors

Sponsor

Shanghai Henlius Biotech

Enrollment

254 participants

Start Date

Dec 29, 2025

Study Type

INTERVENTIONAL

Conditions

NSCLC Advanced/Metastatic Solid Tumors

Summary

This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX37 in patients with advanced/metastatic solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HLX37 for people with advanced/metastatic solid tumors and nsclc. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHLX37

HLX37 will be administered as an intravenous (IV) infusion.

Locations(2)

Shanghai Chest Hospital

Shanghai, China

The Second Affiliated Hospital of Air Force Medical University of the People's Liberation Army of China

Xi'an, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07274813

Related Trials

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

NCT067381601 location

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT0709049930 locations

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784152 locations

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143215 locations

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT073973386 locations